Jounce Therapeutics, Inc.
JNCEDelisted May 4, 2023- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001640455
Jounce Therapeutics, Inc. was delisted on May 4, 2023; its insiders filed their last Form 4 on May 5, 2023; 84 institutions reported holding it in 13F filings for Q1 2023, worth $64.1M in total; no superinvestor held it.
13F holders, Q3 2021
Institutional positions in Jounce Therapeutics, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 115
- −14 vs. Q2 2021
- Shares held
- 36.4M
- +438.6K (+1.2%) vs. Q2 2021
- Total value
- $270.6M
- +$26.1M (+10.7%) vs. Q2 2021
- New holders
- 11
- 44 more added
- Sold out
- 25
- 35 more reduced
1 institution that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting JNCE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 1 | $917.8K |
| Q1 2023 | 84 | $64.1M |
| Q4 2022 | 85 | $39.8M |
| Q3 2022 | 102 | $99.5M |
| Q2 2022 | 102 | $129.3M |
| Q1 2022 | 113 | $287.1M |
| Q4 2021 | 124 | $342.9M |
| Q3 2021 | 115 | $270.6M |
| Q2 2021 | 130 | $244.8M |
| Q1 2021 | 124 | $378.3M |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Jounce Therapeutics, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Goldman Sachs Group Inc | 673,926 | $5.01M | 0.00% | +509,577+310.1% | Added |
| Erste Asset Management GmbH | 779,587 | $5.79M | 0.11% | +120,000+18.2% | Added |
| FMR LLC | 790,934 | $5.88M | 0.00% | 00.0% | Unchanged |
| Acadian Asset Management LLC | 888,365 | $6.60M | 0.03% | +184,446+26.2% | Added |
| Dimensional Fund Advisors LP | 1,047,545 | $7.78M | 0.00% | −179,735−14.6% | Reduced |
| RTW Investments, LP | 1,396,203 | $10.4M | 0.16% | +1,396,203 | New |
| Vanguard Group Inc | 1,443,429 | $10.7M | 0.00% | +36,604+2.6% | Added |
| Citadel Advisors LLC | 1,724,251 | $12.8M | 0.01% | −236,350−12.1% | Reduced |
| Logos Global Management LP | 2,000,000 | $14.9M | 1.07% | +2,000,000 | New |
| Adage Capital Partners GP, L.L.C. | 2,456,023 | $18.2M | 0.04% | +28,000+1.2% | Added |
| BlackRock Inc. | 2,534,851 | $18.8M | 0.00% | +77,752+3.2% | Added |
| OrbiMed Advisors LLC | 2,655,600 | $19.7M | 0.22% | +508,200+23.7% | Added |
| TRV GP II, LLC | 2,697,829 | $20.0M | 88.84% | −1,750,000−39.3% | Reduced |
| TRV GP III, LLC | 3,048,780 | $22.7M | 4.30% | 00.0% | Unchanged |
| PFM Health Sciences, LP | 3,848,822 | $28.6M | 0.93% | +585,989+18.0% | Added |
| Victory Capital Management Inc | 0 | $0 | 0.00% | −485,173−100.0% | Sold out |
| Tekla Capital Management LLC | 0 | $0 | 0.00% | −382,237−100.0% | Sold out |
| HealthCor Management, L.P. | 0 | $0 | 0.00% | −268,295−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −133,300−100.0% | Sold out |
| Jacobs Levy Equity Management, Inc | 0 | $0 | 0.00% | −126,857−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −77,094−100.0% | Sold out |
| First Trust Advisors LP | 0 | $0 | 0.00% | −72,807−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −60,942−100.0% | Sold out |
| HarbourVest Partners LLC | 0 | $0 | 0.00% | −53,260−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −40,853−100.0% | Sold out |
| M&G Investment Management Ltd | 0 | $0 | 0.00% | −36,779−100.0% | Sold out |
| First Quadrant L P | 0 | $0 | 0.00% | −37,800−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −33,322−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −29,928−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −26,064−100.0% | Sold out |
| Engineers Gate Manager LP | 0 | $0 | 0.00% | −24,500−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −22,255−100.0% | Sold out |
| Mass General Brigham, Inc | 0 | $0 | 0.00% | −19,291−100.0% | Sold out |
| Hussman Strategic Advisors, Inc. | 0 | $0 | 0.00% | −15,500−100.0% | Sold out |
| PDT Partners, LLC | 0 | $0 | 0.00% | −15,009−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −12,108−100.0% | Sold out |
| Hancock Whitney Corp | 0 | $0 | 0.00% | −11,664−100.0% | Sold out |
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −11,400−100.0% | Sold out |
| Point72 Hong Kong Ltd | 0 | $0 | 0.00% | −4,606−100.0% | Sold out |
| MV Capital Management, Inc. | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| QS Investors, LLC | – | – | – | – | Not filed |